Evidence map›Paper›PMID 40799645›Full record

ArticleFrontiers in immunology2025

Identification of a TIGIT-expressing CD8

Shouli Cao, Meidan Wang, Weiqiang Sun, Zhibin Ma, Kun Yang, Ting Li, Xuedan Zhu, Yang Pei, Mingyue Pan, Liqun Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. TIGITCancers · 2026
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shouli Cao *Department of Gastroenterology, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Meidan Wang *Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Weiqiang Sun *Department of Hepatobiliary Surgery, General Surgery, Jinan Third People's Hospital, Jinan, Shandong, China.
Zhibin Ma *Department of Gastroenterology The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Kun YangDepartment of Gastrointestinal Surgery, General Surgery, Jinan Third People's Hospital, Jinan, Shandong, China.
Ting LiDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Xuedan ZhuDepartment of Gastroenterology The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yang PeiDepartment of Gastroenterology The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Mingyue PanFaculty of Law, University of Freiburg, Freiburg, Germany.
Liqun WangDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Honglin DingDepartment of Gastroenterology The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TIGIT is an inhibitory immune checkpoint receptor on T cells and NK cells that mediates immunosuppressive effects by binding to ligands on malignant or antigen-presenting cells. In colorectal cancer (CRC), immune checkpoint inhibitors like anti-PD-1 show therapeutic promise, but many patients experience resistance or relapse. Therefore, identifying robust immune biomarkers for predicting disease progression and therapeutic response is critical. Analysis of transcriptomic data from CRC patients revealed that high TIGIT expression is associated with poorer overall and disease-free survival. TIGIT expression also correlated with immune infiltration, particularly CD8

Indexed as

Biomarkers, TumorCD8-Positive T-LymphocytesColorectal NeoplasmsReceptors, ImmunologicT-Lymphocyte SubsetsChemokine CXCL13FemaleHumansLymphocytes, Tumor-InfiltratingMalePrognosisProgrammed Cell Death 1 ReceptorBiomarkers, TumorChemokine CXCL13PDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, humancolorectal cancer (CRC)CXCL13+CD8+ T cellsPD-1T cell immunoreceptor with Ig and ITIM domains (TIGIT)tumor immune microenvironment (TIME)

Identifiers

PMID40799645
PMCPMC12340724

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.